WO2002062333A9 - Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein - Google Patents
Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid proteinInfo
- Publication number
- WO2002062333A9 WO2002062333A9 PCT/US2002/003592 US0203592W WO02062333A9 WO 2002062333 A9 WO2002062333 A9 WO 2002062333A9 US 0203592 W US0203592 W US 0203592W WO 02062333 A9 WO02062333 A9 WO 02062333A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- compound
- compounds
- virus
- Prior art date
Links
- 0 *C1C(*)C2OC(C(*)C(*)CC3)C3C(*)C2CC1 Chemical compound *C1C(*)C2OC(C(*)C(*)CC3)C3C(*)C2CC1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D311/82—Xanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the present invention relates to anti- viral therapy and provides novel methods of inhibiting viral replication.
- retroviruses such as HIV
- HIV is an example of such a hyper-mutable virus. It has diverged into two major species, HIN-1 and HIN-2, each of which has many clades, subtypes and drug resistant variations.
- Combination therapies for retroviruses using, e.g., protease inhibitors and nucleoside analogues, such as AZT, ddl, ddC and d4T, can become ineffectual; the virus develops complete resistance in a relatively short period of time (Birch (1998) AIDS 12:680-681; Roberts (1998) AIDS 12:453-460; Yang (1991) Leukemia 11 Suppl 3:89-92; Demeter (1997) J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14(2): 136-144; Kuritzkes (1996) AIDS 10 Suppl 5:S27-S31). Furthermore, no effective anti-retroviral vaccine is currently available (Bolognesi (1998) Nature 391:638-639; Bangham (1997) Lancet 350:1617-1621).
- the Gag and Gag-Pol proteins in the Retroviridae except for Spumaviruses, contain a highly conserved zinc finger motif (CCHC) within the nucleocapsid p7 ( ⁇ Cp7) protein portion of the polyprotein (see definitions, below).
- CCHC zinc finger motif
- ⁇ Cp7 nucleocapsid p7
- the absolute conservation of the metal chelating cysteine and histidine residues along with other residues of the protein and its in participation in essential functions during early and late virus replication has identified this feature as an antiviral target. Mutations of the chelating residues in the zinc fingers yield a non-infectious virus. Because zinc fingers are identical in most retroviruses, reagents able to inhibit its function have the potential of being broad spectrum anti- iral therapeutic drugs.
- the present invention now provides new methods of inhibiting viral replication using tricyclic compounds that disrupt nucleocapsid nucleic acid binding interactions.
- the invention provides a method of inhibiting viral replication by administration of compounds that disrupt nucleocapsid binding to nucleic acids.
- the invention provides a method of inhibiting replication of a virus, said method comprising: contacting a nucleocapsid protein of the virus with a compound having the formula:
- R 3 is a member selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkyl and substituted or unsubstituted aryl; and
- ring system A is either saturated or mono-unsaturated.
- R 1 , R 5 , R 2 , and R 4 are -OH.
- R 3 is a member selected from the group consisting of
- X 1 , X 2 , X 3 , and X 4 are members independently selected from the group consisting of -H, -F, -CI, -Br, -I and -COOH.
- R 3 is a member selected from the group consisting alkyl substituted with -COOH, alkylene substituted with -COOH and cycloalkyl substituted with -COOH. Often R 3 is a member selected from the group consisting of
- R 6 is a member selected from substituted alkyl and unsubstituted alkyl; and m and n are independently integers from 0 to 10.
- the compound is a member selected from the group consisting of
- the virus is a retrovirus.
- the virus is a retrovirus derived from a avian sarcoma and leukosis retroviral group, a mammalian B-type retroviral group, a human T cell leukemia and bovine leukemia retroviral group, a D-type retroviral group, a murine leukemia-related group, or a lentivirus group.
- the retrovirus is an HIN-1, an HIV-2, an SIN, a BIN, an EIAN, a Nisna, a CaEN, an HTLN-1, a BLN, an MPMN, an MMTN, an RSN, an MuLN, a FeLN, a BaEN, or an SSN retrovirus.
- the retrovirus is HTN-l.
- the contacting of the virus with the compound can be performed in vivo.
- the compound can be administered to inhibit the transmission of the virus.
- the compound can be administered intra-vaginally or intra-rectally to inhibit the transmission of the virus.
- the compound can be administered to a human as a pharmaceutical formulation.
- the compound can be administered to an animal as a veterinary pharmaceutical formulation.
- the method further comprises contacting the virus with a non-tricyclic anti-retroviral agent.
- the anti-retroviral agent can be a nucleoside analogue, a protease inhibitor, or a non-nucleoside reverse trancriptase inhibitor ( ⁇ RTI).
- the nucleoside analogue can be AZT, ddCTP or DDL
- the protease inhibitor can be Indinavir, Saquinavir, or Ritonavir and ⁇ RTI include nevirapine and efavirenz.
- the invention also provides a method for inactivating a virus, wherein the contacting of the virus with the compound can be performed in vitro.
- the contacting of the retrovirus with the compound can be performed in a blood product, blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, food or drink.
- the compound is administered to a human as a pharmaceutical formulation. Often the compound is administered intra- vaginally or intra-rectally to inhibit the transmission of the virus.
- the compound is administered to an animal as a veterinary pharmaceutical formulation.
- the pharmaceutical formulation comprises a unit dose of a tricyclic compound described herein.
- the pharamceutical formulation further comprises a pharmaceutical exceipient.
- Figure 1 shows the names and numbering system for gallein and lfuorescein derivative test compounds described in the Example section.
- the numbering system for the benzoic acid group will change, depending on the form of the molecule (lactoid or quinoid) and the substituents on the ring on the benzoic acid ring system.
- Figure 2 shows database structures and NC-p7 binding constants for structurally similar actives from primary screen. Structures of actives as listed in the NCI chemistry database. Dissociation constants were determined using solution inhibition analysis on the BIAcore system.
- Figure 4 shows the results of a solution inhibition of NC-p7 with 157412-10 and fluorescein.
- NC-p7 (50nM) was incubated with an increasing concentration of either 157512-10 or fluorescein. Uninhibited NC-p7 bound to d(TG)4 immobilized on a BIAcore chip, the amount of NC-p7 was calculated using a standard curve.
- Figure 5 shows the binding of 157412-10 to NC-p7 mutants.
- the direct binding of 157412-10 to NC-p7 was monitored by the quenching of the tryptophan fluorescence (excitation 295nm, emission 350nm).
- NC-p7 wild type and mutants (400nM) were incubated with increasing concentrations of 157412-10.
- FIGs 6a and 6b Structures of synthetic variants of NSC 157412-10 are shown in Figure 6a.
- Figure 6b shows the solution inhibition of NC-p7 with synthetic variants of NSC 157412-10.
- Figure 7 shows the antiviral activity of 157412-10 and related compounds.
- Figures 7A and 7B shows the effects of NSC 157412-10 and its synthetic variants on early stages of HIV replication assessed in MAGI cells.
- MAGI cells were infected with HIVIIIB and cultured in the absence or presence of increasing concentrations of NSC 157412-10 or its synthetic version, 4436-42-1.
- the anti-HIV activity is expressed as the percent H1N infected cells of untreated control. Both compounds were tested in triplicate at each dose. The values shown are mean with SD.
- NSC 157412-10 and 4436-42-1 exhibited similar levels of anti-HIV activity in a dose dependent manner.
- NC protein contains two zinc fingers separated by only seven amino acids (Henderson (1992) J. Virol. 66:1856). Both fingers are essential for infectivity (Aldovini (1990) J. Virol. 64:1920; Gorelick (1990) J Virol 64:3207). Agents have been identified that target this regions, see, e.g., WO97/44064, W09965871, U.S. Patents 6,001,555 and 6,046,228.
- the present invention employs compounds comprising a tricyclic ring structure which bind to the nucleocapsid with high affinity and thereby inhibit interaction with nucleic acid molelcules.
- R 3 is a member selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkyl and substituted or unsubstituted aryl. Ring system A is fully saturated or mono-unsaturated.
- the method makes use of compounds in which R 3 is a member selected from the group consisting of:
- X 1 , X 2 , X 3 , and X 4 are members independently selected from the group consisting of -H, -F, -CI, -Br, -I and -COOH.
- the method of the invention utilizes compounds in which R 3 is a member selected from the group consisting alkyl substituted with -COOH, alkylene substituted with -COOH and cycloalkyl substituted with -COOH.
- R 3 is even more preferably, a member selected from: wherein R 6 is a member selected from substituted alkyl and unsubstituted alkyl; and m and n are independently integers from 0 to 10.
- ring systems C and B are members independently selected from substituted or
- R and R 22 represent groups that are independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- Ring system A is either fully saturated or mono-unsaturated.
- Presently preferred compounds of use in the present invention having the structural motif set forth in Formula II are displayed in FIG. 1.
- the method of the invention utilizes compounds having a structure according to Formula III:
- R 7 and R 8 are members independently selected from -N0 2 , halo, -OH, and substituted or unsubstituted alkyl.
- R 3 is a member selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkylene, substituted or unsubstituted cycloalkyl and substituted or unsubstituted aryl; and ring system A is fully saturated or mono- unsaturated.
- the present invention is directed to the use of tricyclic compounds described herein to disrupt the association of a viral nucleocapsid protein to nucleic acid.
- Many of these compounds are known, see, e.g., the National Cancer Institute chemical repository although none have been used as anticancer (or other indication) agents prior to the present application.
- Chemical structural information on some of the claimed compound is available via the DTP website: http://dtp.nci.nih.gov. Methods of synthesizing such chemicals are known to those of skill in the art.
- new tricyclic compounds according to Formula I, II, or III that inhibit viral replication as described herein can be synthesized using techniques readily apparent to those of skill in the art.
- tricyclic compound refers to a compound having a structure corresponding to that set out in Formula I, II, or III. These formulas define a three- dimensional phamacophore which interacts with the nucleocapsid protein by forming at least one hydrogen bond. Other tricyclic compounds to exploit the present and other hydrogen bonding modalities will be apparent to those of skill in the art.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (i.e. Ci-Cio means one to ten carbons).
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl, (cyclohexyl)methyl, cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like.
- An unsaturated alkyl group is one having one or more double bonds or triple bonds.
- alkyl groups examples include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3- (1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers.
- alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as “heteroalkyl.” Alkyl groups which are limited to hydrocarbon groups are termed "homoalkyl".
- alkylene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
- an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
- a “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms.
- alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and from at least one heteroatom selected from the group consisting of O, N, Si and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) O, N and S and Si may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 - CH 2 -S-CH 2 CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
- heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like).
- cycloalkyl and “heterocycloalkyl”, by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3- cyclohexenyl, cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1 -(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like.
- halo or halogen
- haloalkyl by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
- terms such as “haloalkyl,” are meant to include monohaloalkyl and polyhaloalkyl.
- halo(C 1 -C 4 )alkyl is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (up to three rings) which are fused together or linked covalently.
- heteroaryl refers to aryl groups (or rings) that contain from zero to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4- isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3- thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquino
- aryl when used in combination with other terms (e.g., aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
- arylalkyl is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy)propyl, and the like).
- alkyl group e.g., benzyl, phenethyl, pyridylmethyl and the like
- an oxygen atom e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(l- naphthyloxy
- R', R", R'" and R" each preferably independently refer to hydrogen, and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(Cr C 4 )alkyl groups.
- each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present.
- R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7- membered ring.
- -NR'R is meant to include, but not be limited to, 1- pyrrolidinyl and 4-morpholinyl.
- alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF 3 and -CH 2 CF 3 ) and acyl (e.g. , -C(0)CH 3 , -C(0)CF 3 , -C(0)CH 2 OCH 3 , and the like).
- Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(0)-(CRR' 2 ) q -U-, wherein T and U are independently -NR-, -0-, -CRR'- or a single bond, and q is an integer of from 0 to 3.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 ) r -B-, wherein A and B are independently -CRR'-, -0-, -NR-, -S-, -S(O)-, -S(0) -, -S(0) 2 NR'- or a single bond, and r is an integer of from 1 to 4.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR') s -X-(CR"R'") t -, where s and t are independently integers of from 0 to 3, and X is -0-, -NR'-, -S-, -S(O)-, -S(0) 2 -, or -S(0) 2 NR'-.
- the substituents R, R', R" and R'" are preferably independently selected from hydrogen or substituted or unsubstituted (C ⁇ -C 6 )alkyl.
- the term "heteroatom” is meant to include oxygen (O), nitrogen (N), sulfur (S) and silicon (Si).
- salts are meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein.
- base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.
- pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p- tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the present invention provides compounds, which are in a prodrug form.
- Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention.
- prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
- Contacting refers to the act of bringing components of a reaction into adequate proximity such that the reaction can occur. More particularly, as used herein, the term “contacting” can be used interchangeably with the following: combined with, added to, mixed with, passed over, flowed over, etc.
- Gag-Pol protein refers to the polyprotein translation product of HIV- 1 or other retroviruses, as described, e.g., by Fehrmann (1997) Virology 235:352359; Jacks (1988) N ⁇ twre 331 :280-283.
- the "Gag protein” is processed by a viral protease to yield mature viral proteins, see, e.g., Humphrey (1997) Antimicrob. Agents Chemother. 41:1017-1023; Karacostas (1993) Virology 193:661-671.
- halogen is used herein to refer to fluorine, bromine, chlorine and iodine atoms.
- isolated when referring to a molecule or composition, such as, for example, a tricyclic compound of the invention, a tricyclic-complexed polypeptide or virus, or a tricyclic-inactivated virus, means that the molecule or composition is separated from at least one other compound, such as a protein, other nucleic acids (e.g., R ⁇ As), or other contaminants with which it is associated in vivo or in its naturally occurring state.
- a compound, polypeptide or virion is considered isolated when it has been isolated from any other component with which it is naturally associated, e.g., cell membrane, as in a cell extract, serum, and the like.
- An isolated composition can, however, also be substantially pure.
- nucleocapsid protein or " ⁇ C protein” refers to the retroviral nucleocapsid protein, which is an integral part of the virion nucleocapsid, where it coats the dimeric R ⁇ A genome, as described by, e.g., Huang (1997) J. Virol. 71 :4378-4384; Lapadat-Tapolsky (1997) J. Mol. Biol.
- HIV-l's nucleocapsid protein is termed " ⁇ Cp7,” see also Demene (1994) Biochemistry 33:11707-11716.
- All NC proteins of the Oncovirinae and Lentivirinae subfamilies of Retroviridae contain sequences of 14 amino acids with 4 invariant residues, Cys(X) 2 Cys(X) 4 His(X) 4 Cys, (L.E. Henderson et al. J. Biol. Chem. 256, 8400 (1981)) which chelate zinc through histidine imidazole and cysteine thiolates with a K d less than 10 "13 (J.M. 5 Berg, Science 232, 485 (1986); J.W.
- retroviruses which possess at least 0 one CCHC type zinc finger per nucleocapsid protein include, but are not limited to, HIV-1, H1N-2, SIV, BIV, EIAV, Visna, CaEV, HTLV-1, BLV, MPMV, MMTV, RSV, MuLV, FeLV, BaEV, and SSV.
- retrovirus refers to viruses of the Retroviridae family, which typically have ssR ⁇ A transcribed by reverse transcriptase, as defined by, e.g., 5 P. K. Vogt, "Historical introduction to the general properties of retroviruses," in Retroviruses, eds. J. M. Coffin, S. H. Hughes and H. E. Varmus, Cold Spring Harbor Laboratory Press, 1997, pp 1-26; Murphy et al.
- Retroviridae family members containing zinc finger motif-containing polypeptides and whose replication can be inhibited by the tricyclic compounds of the invention include avian sarcoma and leukosis retroviruses (alpharetroviruses), mammalian B-type retroviruses (betaretrovirus) (e.g., mouse mammary tumor virus), human T cell leukemia and bovine leukemia
- retroviruses e.g., human T-lymphotropic virus 1
- murine leukemia- related group gammaretro viruses
- D-type retroviruses e.g., Mason- Pfizer monkey virus
- Lentiviruses include bovine, equine, feline, ovine/caprine, and primate lentivirus groups, such as human immunodeficiency virus 1 (HJN- 1). Examples of particular species of viruses whose replicative capacity is affected by the
- tricyclic compounds of the invention include HIN-1, HIN-2, SIN, BIN, EIAN, Visna, CaEV, HTLV-1, BLV, MPMV, MMTV, RSV, MuLV, FeLV, BaEV, and SSV retrovirus.
- viruses that include proteins with zinc fmger domains that interact with nucleic acid can also be targeted with the tricyclic compounds as described herein.
- human papilloma virus E6 and E7 proteins contain zinc finger domains that can be targets for binding by this series of compounds (Beerheide et al, JNatl Cancer Inst 91:1211- 20, 1999).
- the hepatitis C virus genome codes for zinc finger-containing protens that can be targeted with the tricyclic compounds.
- the ability of the compound to bind to a viral nucleocapsid protein is often evaluated.
- the assessment of binding affinity can be determined using techniques known by one or ordinary skill in the art (see, e.g., WO97/44064). For example tryptophan fluorescence quenching or other binding assays such as the BIAcore chip technology can be used in order to determine the binding affinity of a tricyclic compound for the viral zinc finger-containing protein. Examples of these procedures are further provided in Example 1. As appreciated by one of skill, other assay procedures can be used to provide an equivalent assessment for binding of compounds to any viral nucleocapsis protein.
- binding affinity is assessed and compounds that bind to the nucleocapsid at a K D of less than 200 ⁇ M, determined, e.g., using a solution inhibition assay as described in the Examples, are then analyzed for anti- viral activity in vitro.
- a tricyclic compound is within the scope of the invention if it displays any antiviral activity (i.e., any ability to decrease the cytopathic effect or diminish the transmission of or the replicative capacity of a virus).
- the antiviral activity can be determined empirically by clinical observation or objectively using any in vivo or in vitro test or assay, e.g., the XTT cytoprotection assay (described herein), measuring Tat-induced activity (as in the HeLa-CD4-LTR-beta-gal (MAGI cells) assay and detecting Tat-induced beta-galactosidase activity, see, e.g., Tokunaga (1998) J Virol. 12:6251-6259), and the like.
- a tricyclic compound with any degree of measurable antiviral activity is within the scope of the invention.
- virus e.g., HIV-I RF
- MOI 0.01
- XTT 2,3-bis[2-methoxy- 4-nitro-5- sulfophenyl] -5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide
- HIN-1 RF HIN-1 RF
- test compounds tricyclic compounds and controls
- the cultures are incubated for seven days.
- control cultures without protective compounds i.e., compounds with anti- viral activity
- replicate virus induce syncytia, and result in about 90% cell death.
- the cell death is measured by XTT dye reduction.
- XTT is a soluble tetrazolium dye that measures mitochondrial energy output, similar to MTT.
- Positive controls using dextran sulfate (an attachment inhibitor) or 3'-Azido -2'-3'-dideoxythymidine, AZT (a reverse transcriptase inhibitor) are added to each assay. Individual assays are done in duplicate using a sister plate method.
- any virus can be grown in culture, or in an in vivo (animal) model, in the presence or absence of a tricyclic compound or a tricyclic-containing pharmaceutical formulation to test for anti- viral, viral transmission-inhibiting activity and efficacy.
- Any virus, assay or animal model which would be apparent to one of skill upon review of this disclosure can be used, see, e.g., Lu (1997) Crit. Rev. Oncog. 8:273-291; Neildez (1998) Virology 243:12-20; Geretti (1998) J. Gen. Virol.
- any measurable decrease in the viral load of a culture grown in the presence of a tricyclic test compound as compared to a positive or negative control compound is indicative of an anti-viral, transmission-inhibiting effect.
- any relevant criteria can be used to evaluate the antiviral efficacy of a tricyclic composition or tricyclic-containing formulation.
- the tricyclic compounds of the invention of the invention prevent the binding of viral nucleocapsid protein to nucleic acids.
- the ability of tricyclic compounds to bind to the viral nucleocapsid is assessed in a binding assay using the targeted nucleocapsid protein, often a retroviral protein.
- the viral nucleocapsid proteins to detect the binding and antiviral activity of the tricyclic compounds are typically produced using recombinant technology. General laboratory procedures for the cloning and expression of nucleocapsid proteins can be found, e.g., current editions of Sambrook, et al, Molecular Cloning A Laboratory Manual (2nd Ed.), Vol.
- nucleocapsid proteins including nucleic acids, proteins and viral sources, are publicly available, for example, through electronic databases, such as, e.g., The National Center for Biotechnology Information at http://www.ncbi.nlm.nih.gov/Entrez/, or, The National Library of Medicine at http ://www.ncbi.nlm.nih.gov/PubMed7.
- the DNA encoding the polypeptide or peptide of interest are first cloned or isolated in a form suitable for ligation into an expression vector. After ligation, the vectors containing the DNA fragments or inserts are introduced into a suitable host cell for expression of the recombinant polypeptides. The polypeptides are then isolated from the host cells.
- the nucleic acids may be present in transformed or transfected whole cells, in a transformed or transfected cell lysate, or in a partially purified or substantially pure form.
- nucleic acid manipulation of genes encoding zinc finger-containing proteins such as subcloning nucleic acid sequences into expression vectors, labeling probes, DNA hybridization, and the like are described, e.g., in Sambrook and Ausubel, supra.
- a recombinantly engineered cell such as bacteria, yeast, insect, or mammalian cells. It is expected that those of skill in the art are knowledgeable in the numerous expression systems available for expression of the recombinantly produced proteins. No attempt to describe in detail the various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.
- the expression of natural or synthetic nucleic acids encoding polypeptides will typically be achieved by operably linking the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector.
- the vectors can be suitable for replication and integration in either prokaryotes or eukaryotes.
- Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding recombinant polypeptides.
- expression plasmids which contain, at the minimum, a promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.
- the invention also provides a method of using a composition comprising a bio-organic or other material and an amount of a tricyclic compound of the invention effective to inactivate any virus (susceptible to inactivation by a tricyclic compound) which is or may contaminate the material.
- the material can be bio-organic, such as, e.g., blood plasma, nutrient media, protein, a pharmaceutical, a cosmetic, a sperm or oocyte preparation, cells, cell cultures, bacteria, viruses, foods, drinks.
- a tricyclic compound of the invention can be in the form of a composition which is applied to any of the above materials as a viricidal reagent and removed before the material's use.
- the viricidal composition can contain a mixture of different tricyclic compounds of the invention in varying amounts.
- tricyclic compounds can be added to cell cultures to reduce the likelihood of viral contamination, providing added safety for the laboratory workers.
- the invention also provides pharmaceutical formulations comprising the tricyclic compounds of the invention.
- These tricyclic compounds are used in pharmaceutical compositions that are useful for administration to mammals, particularly humans, for the treatment of viral, especially retroviral, infections.
- the compounds of the invention can be formulated as pharmaceuticals for administration in a variety of ways. Typical routes of administration include both enteral and parenteral. These include, e.g., without limitation, subcutaneous, intramuscular, intravenous, intraperitoneal, intramedullary, intrapericardiac, intrabursal, oral, sublingual, ocular, nasal, topical, transdermal, transmucosal, or rectal.
- the mode of administration can be, e.g., via swallowing, inhalation, injection or topical application to a surface (e.g., eyes, mucous membrane, skin).
- a surface e.g., eyes, mucous membrane, skin.
- Particular formulations typically are appropriate for specific modes of administration.
- Various contemplated formulations include, e.g., aqueous solution, solid, aerosol, liposomal and transdermal formulations. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of "Remington's Pharmaceutical Sciences” (Maack Publishing Co, Easton PA).
- aqueous solutions that can be used in formulations for enteral, parenteral or transmucosal drug delivery include, e.g., water, saline, phosphate buffered saline, Hank's solution, Ringer's solution, dextrose/saline, glucose solutions and the like.
- the formulations can contain pharmaceutically acceptable auxiliary substances to enhance stability, deliverability or solubility, such as buffering agents, tonicity adjusting agents, wetting agents, detergents and the like.
- Additives can also include additional active ingredients such as bactericidal agents, or stabilizers.
- the solution can contain sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate or triethanolamine oleate.
- These compositions can be sterilized by conventional, well-known sterilization techniques, or can be sterile filtered.
- the resulting aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
- Aqueous solutions are appropriate for injection and, in particular, for intravenous injection.
- the intravenous solution can include detergents and emulsifiers such as lipids.
- Aqueous solutions also are useful for enteral administration as tonics and administration to mucous or other membranes as, e.g., nose or eye drops.
- the composition can contain a tricyclic compound in an amount of about 1 mg/ml to 100 mg/ml, more preferably about 10 mg/ml to about 50 mg/ml.
- Solid formulations can be used for enteral administration. They can be formulated as, e.g., pills, tablets, powders or capsules.
- conventional nontoxic solid carriers can be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like.
- a pharmaceutically acceptable nontoxic composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10%-95% of active ingredient.
- a non-solid formulation can also be used for enteral (oral) administration.
- the carrier can be selected from various oils including those of petroleum, animal, vegetable or synthetic origin, e.g., peanut oil, soybean oil, mineral oil, sesame oil, and the like. See Sanchez, et al, U.S. Patent No. 5,494,936.
- Suitable pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like.
- Nonionic block copolymers synthesized from ethylene oxide and propylene oxide can also be pharmaceutical excipients; copolymers of this type can act as emulsifying, wetting, thickening, stabilizing, and dispersing agents, see, e.g., Newman (1998) Crit. Rev. Ther. Drug Carrier Syst. 15:89-142.
- a unit dose form such as a tablet, can be between about 50 mg/unit to about 2 grams/unit, preferably between about 100 mg/unit to about 1 gram/unit.
- Systemic administration can also be by transmucosal or transdermal means.
- penetrants appropriate to the barrier to be permeated can be used in the formulation.
- penetrants are generally known in the art, and include, e.g., for transmucosal administration, bile salts and fusidic acid derivatives.
- detergents can be used to facilitate permeation.
- Transmucosal administration can be through nasal sprays, for example, or using suppositories.
- the agents are formulated into ointments, creams, salves, powders and gels.
- the transdermal delivery agent can be DMSO.
- Transdermal delivery systems can also include, e.g., patches.
- the tricyclic compounds can also be administered in sustained delivery or sustained release mechanisms, which can deliver the formulation internally.
- sustained delivery or sustained release mechanisms can deliver the formulation internally.
- biodegradeable microspheres or capsules or other biodegradeable polymer configurations capable of sustained delivery of a composition can be included in the formulations of the invention (see, e.g., Putney (1998) Nat. Biotechnol 16:153-157).
- the tricyclic compound formulation can be delivered using any system known in the art, including dry powder aerosols, liquids delivery systems, air jet nebulizers, propellant systems, and the like. See, e.g., Patton (1998) Biotechniques 16:141-
- inhalation delivery systems by, e.g., Dura Pharmaceuticals (San Diego, CA) , Aradigm
- the pharmaceutical formulation can be administered in the form of an aerosol or mist.
- the formulation can be supplied in finely divided form along with a surfactant and propellant.
- the surfactant preferably is soluble in the propellant.
- Representative of such agents are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride such as, for example, ethylene glycol, glycerol, erythritol, arabitol, mannitol, sorbitol, the hexitol anhydrides derived from sorbitol, and the polyoxyethylene and polyoxypropylene derivatives of these esters.
- the surfactant can constitute 0.1%-20% by weight of the composition, preferably 0.25%-5%.
- the balance of the formulation is ordinarily propellant.
- Liquefied propellants are typically gases at ambient conditions, and are condensed under pressure.
- suitable liquefied propellants are the lower alkanes containing up to 5 carbons, such as butane and propane; and preferably ffuorinated or fluorochlorinated alkanes. Mixtures of the above can also be employed.
- a container equipped with a suitable valve is filled with the appropriate propellant, containing the finely divided compounds and surfactant. The ingredients are thus maintained at an elevated pressure until released by action of the valve. See, e.g., Edwards (1997) Science 276:1868-1871.
- a nebulizer or aerosolizer device for administering tricyclic compounds of this invention typically delivers an inhaled dose of about 1 mg/m 3 to about 50 mg/m 3 . Delivery by inhalation is particular effective for delivery to respiratory tissues for the treatment of respiratory conditions including an inflammatory component.
- the tricyclic compound of the invention are used in the treatment and prevention of viral infection, particularly, retroviral infections.
- the amount of tricyclic compound adequate to accomplish this is defined as a "therapeutically effective dose.”
- the dosage schedule and amounts effective for this use, i.e., the "dosing regimen,” will depend upon a variety of factors, including frequency of dosing, the stage of the disease or condition, the severity of the disease or condition, the general state of the patient's health, the patient's physical status, age and the like. In calculating the dosage regimen for a patient, the mode of administration also is taken into consideration.
- the dosage regimen must also take into consideration the pharmacokmetics, i.e., the tricyclic compound's rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g.; the latest Remington's edition, supra).
- Single or multiple administrations of the compositions can be carried out with dose levels and pattern being selected by the treating physician.
- the pharmaceutical formulations should pro-vide a quantity of a tricyclic compound sufficient to treat the patient effectively.
- the total effective amount of a tricyclic compound of the present invention can be administered to a subject as a single dose, either as a bolus or by infusion over a relatively short period of time, or can be administered using a fractionated treatment protocol, in which the multiple doses are administered over a more prolonged period of time.
- concentration of a tricyclic compound of the present invention required to obtain an effective dose in a subject depends on many factors including, e.g., the pharmacokmetics of the prodrug and of its hydrolysis product, the age and general health of the subject, the route of administration, the number of treatments to be administered and the judgment of the prescribing physician. In view of these factors, the skilled artisan would adjust the dose so as to provide an effective dose for a particular use.
- the tricyclic compounds can be used in conjunction with other therapies used for the treatment of viral infection.
- the tricyclic compounds can be used in a therapeutic regimen that includes nucleoside analog therapy an protease inhibitor therapy.
- the invention also provides an isolated and inactivated virus, where the virus is inactivated by a method comprising contacting the virus with a tricyclic compound compound of the invention, wherein contacting said virus with said compound inactivates said virus.
- the isolated and inactivated virus further comprises a vaccine formulation.
- the tricyclic compound-complexed, inactivated viruses of the invention are used in vaccine formulations that are useful for administration to mammals, particularly humans to treat and generate immunity to of a variety of viral diseases, particularly retroviral infections, such as HIV-1.
- the vaccine formulations can be given single administrations or a series of administrations. When given as a series, inoculations subsequent to the initial administration are given to boost the immune response and are typically referred to as booster inoculations.
- the vaccines of the invention contain as an active ingredient an immunogenically effective amount of a tricyclic compound-complexed, inactivated, virus.
- Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(D-lysine: D-giutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like.
- the vaccines can also contain a physiologically tolerable (acceptable) diluent such as water, phosphate buffered saline, or saline, and further typically include an adjuvant.
- Adjuvants such as incomplete Freund's adjuvant, aluminum phosphate, aluminum hydroxide, or alum are also advantageously used to boost an immune response.
- Tricyclic compound Inactivated Viruses and Tricyclic compound-Complexed Proteins
- tricyclic compound-inactivated viruses and tricyclic compound-complexed viral proteins have a variety of uses.
- tricyclic compound-complexed viral proteins or tricyclic compound-inactivated viruses can be used as reagents for the detection of corresponding anti-viral antibodies or as crystallization reagents for X-ray crystallization analysis or other ultrastructural studies, see, e.g., Yamashita (1998) J. Mol. Biol. 278:609-615; Wu (1998) Biochemistry 37:4518-4526.
- kits embodying the methods herein optionally comprise one or more of the following: (1) a tricyclic component as described herein; (2) instructions for practicing the methods described herein, and/or for using the tricyclic component; (3) one or more assay component; (4) a container for holding tricyclic compounds, assay components, or apparatus components useful for manipulating tricyclic compounds or practicing the methods herein, and, (5) packaging materials.
- the present invention provides for the use of any compound, kit, or kit component herein, for the practice of any method or assay herein, and/or for the use of any apparatus or kit to practice any assay or method herein.
- Example 1 Binding of tricyclic compounds to viral nucleocapsid protein.
- Example la High-throughput screen.
- a high throughput screen was devised to identify reversible antagonists of the NC-p7 oligonucleotide interaction.
- a PBS based buffer was designed (PBS/1 O ⁇ M zinc chloride/1 OmM ⁇ -mercaptoethanol/0.05% Tween) to select inhibitors that had non-covalent, non-redox and non-chelating activity.
- the caveat was that assays done in an excess of either reducing agent or zinc would eliminate the possibility of identifying compounds whose inhibition of NC-p7 was through a covalent, redox or chelating based mechanism.
- a set of ⁇ 2000 compounds, the "Diversity Set" was selected for screening that represents a broad range of three dimensional pha ⁇ nacophores that are found in the NCI's repository of > 140, 000 compounds.
- NC-p7 was immobilized on a polystyrene 96 well plate and then blocked with 2% BSA. The plates were washed 3 times with PBS/0.05% Tween, and were then incubated with 5nM biotinylated 28mer and lO ⁇ M of the compound (in 20% DMSO) for 1 hour.
- This 28 base oligonucleotide contains 19 bases from the 3' end of U5 and is one used previously (Fisher et al, J Virol 72:1902-9, 1998)and was also used in competitive hybridization experiments by Tsuchihashi and Brown (Tsuchihashi, 1994).
- the plates were washed again with PBS/0.05% Tween and incubated with nutravidin-horse radish peroxidase (40ng/ml) for an hour to detect bound biotinylated 28mer.
- the plates were washed with PBS/0.05% Tween and developed with Supersignal reagent. Each plate had 8 positives controls (5mM EDTA) and 8 negative controls (20% DMSO alone).
- the Z factor (a statistical parameter to evaluate quality of high throughput screens) was calculated for each plate to ensure adequate performance through all the plates utilized in the screen.
- the activity threshold was established as 100% inhibition and 26 positives were identified.
- This example shows an assay to determine the K D of a tricyclic compound for the HIN-1 nucleocapsid protein (referred to in the example as p7).
- BIAcore ® solution inhibition assay e.g., Christensen et al, Anal Biochem 249:153-164, 1997; Fivash et ⁇ /., Curr. Opm. Biotechnol 9:97-101, 1998; Fisher et al, J. Virol. 72:1902-1909, 1998) in which NP-p7 was incubated with increasing amounts of sample and injected over d(TG) 4 immobilized on the flow cell surface. Uninhibited NC-p7 was quantified using a NC- p7 standard curve. All of the five samples were confirmed as active in the BiAcore assay.
- the dissociation constant for binding to NC-p7 was calculated for each sample (NSC's 119889, 119910, 1 . 19911, 119913, 119915 with Kd's of 253, 407, 350, 379, 394nM respectively).
- Example 2 Anti- viral activity of tricyclic compounds The following example shows the assessment of anti- viral activity of the compounds described herein.
- cell based anti-HIV screening was performed in CEM-SS cells, using XTT-cytoprotection assay. Compounds were ranked as active (80-100% protection from HIV infection), moderate (50-79%) protection) and inactive (0-49% protection). Generally, samples that had lower Kd's, i.e., bound tightly, were found to be active in the cell based assay.
- the lead sample from this analysis was NSC 119889 (recorded in the NCI chemical database as 2,3,4,5-tetrabromo-6-(3,6-dihydroxy-9H-xanthen- 9-yl)benzoic acid) with a Kd of 259nM.
- Example 3 Characterization of the binding of an exemplary tricyclic ring compound to NC- p7.
- Sample NSC 157412 (2,3,4,5-tetrachloro-6-(4,5,6-trihydroxy-3-oxo-3H- xanthen-9-yl)benzoic acid; Kd 1850nM) was recorded in the NCI chemistry database as having chlorine residues substituting the bromine residues found inNSC 119889 and two additional hydroxyl groups on the tricyclic ring. As this sample was found to be less heterogeneous than NSC 119889, active material was purified from NSC 157412 ("la" in Figure 1).
- NSC 157412-10 Binding of NSC 157412-10 to NC variants.
- NSC 157412-10 bound equally well to the two mutant NC-p7's compared to the wild type ( Figure 5).
- NSC 157412-10 Binding of synthetic forms of NSC 157412-10 to NC-p7.
- NSC 157412-10 2,3,4,5- tetrachloro-6-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid
- 4436-26-1 is the same as NSC 157412 but the bromine residues have been changed to chlorines.
- NSC 119889 (2,3,4,5-tetrabromo-6-(3,6-dihydroxy-9H- xanthen-9-yl)benzoic acid) ( Figure 6a). These compounds were assayed for their activity towards NC-p7 by solution inhibition analysis ( Figure 6b). Both 4436-26-1 and 4436-42-1 inhibit NC-p7 stoichiometrically; this further confirms the activity in NSC 157412-10 is the same as 4436-42-1, that of 2,3,4,5-tetrachloro-6-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9- yl)benzoic acid. These data also suggest that 4436-26-1 is the active material in the crude NSC 119889 sample.
- Sample 4436-8-1 had no activity towards NC-p7, 4436-26-1, which differs from 4436-8-1 in that it has two additional hydroxyls at positions 4 and 5 on the tricyclic ring. Fluorescein also lacks these two hydroxyls groups and has no activity towards NC-p7. Thus, these two hydroxyl groups can play a role in the inhibitory activity of this class of compound.
- Molecular modeling of 4436-42-1 and 4436-8-1 The results of the docking analysis suggest two candidate docking sites for each zinc finger, located on opposite sides of residues involved in zinc coordination. These sites are referred to as the distal and proximal sites for each zinc finger, and yield four putative docking sites.
- 4436-8-1 yielded acceptable initial dockings at both the distal and proximal sites of the amino terminal zinc finger and only the distal site for the carboxyl terminal finger.
- 4436-42-1 could be docked initially at only the proximal sites of each zinc finger. Based on minimal rounds of minimization and molecular dynamics simulations, 4436-42-1, when docked at the proximal site of the carboxyl terminal zinc finger, yields the lowest relative total energy score. In general, the total energy scores for 4436-42-1 at this site were consistently lower than the lowest energy scores for 4436-8-1 when at all candidate sites. As a result of this calculation, the best docked positions of 4436-42-1 were further analyzed.
- This example demonstrates the assessment of anti- viral activity of the tricyclic compounds in vivo.
- a variety of models can be used to show the in vivo activity of the compounds.
- anti- viral activity can be assessed in a model of HIN-1 infection that uses mice engrafted with human cells expressing CD4 + (see, e.g., http://www.niaid.nih.gov/daids/PDATguide/ ⁇ rVThera.htm). These animals are therefore susceptible to HIN-1 infection.
- SCLD-Hu model SCID mice are implanted with human fetal thymus and liver tissue.
- HIN-1 -infected mice are treated with a subject tricyclic compound and assessed for a reduction in detectable HIN-1.
- Antiviral efficacy is demonstrated by a reduction in virus load (p24 and RNA) and protection of CD4 + cells from virus-induced depletion.
- the compounds can be evaluated either alone or in combination with other agents. Pharmacokinetic and toxicology evaluations and studies to determine optimal routes and schedules of administration can also be performed.
- other animal models e.g. , Rhesus monkeys infected with SIN, can also be used to demonstrate the anti- viral activity of the compounds in vivo.
- RESULTS Reagents Oligonucleotides were synthesized with biotin at the 3 ' end. Recombinant HIN-1 ⁇ C-p7 protein contained 55 amino acids and the sequence was from the MN isolate of HIV- 1. Wild type, SSHS NC and finger switch mutants were prepared as previously described (Wu et al, J Virol 70:7132-42, 1996; Guo et al, J Virol. 74:8980-8, 2000; and Gorelick, et al, J Virol. 67:4027-36, 1993). The "Diversity Set" of compounds was provided by the Developmental Therapeutics Program, at the National Cancer Institute .
- NC-p7 high-throughput screen.
- the assay was performed using a Tomtec Quadra robotic system.
- NC protein was immobilized on Costar (Corning, NY) high-bind polystyrene 96 well plates by incubating 100 ⁇ l 250nM NC-p7 in phosphate buffered saline (PBS)/ lO ⁇ M zinc chloride/1 OmM ⁇ -mercaptoethanol 0.05% Tween overnight at 4°C. 200 ⁇ l of 2% BSA in PBS/1 O ⁇ M zinc chloride/1 OmM ⁇ -mercaptoethanol/0.05% Tween was added and incubated at room temperature for 1-2 hours in order to block the plates.
- PBS phosphate buffered saline
- O ⁇ M zinc chloride 1 OmM ⁇ -mercaptoethanol/0.05% Tween
- Anti-HIV activity assays Anti-HIV activity was initially screened in a human T-cell line CEM-SS, infected with HIV-I RF in the absence or presence of increasing concentrations of the test compound. The protection from HIV-induced cytopathic effect was determined by the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay, as previously described (Weislow et al, JNatl Cancer Inst 81:577 '- 86; 1989).
- XTT 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide
- AZT and dextran sulfate were included as control compounds for anti-HIV activity.
- the cells were maintained at 37°C with 5% C0 2 -containing humidified air for 6 days. Cell viability was quantified by absorbance at 450mn after 4-hour incubation with XTT (0.2mg/ml). Controls were included to correct absorbance readings of naturally colored compounds. Toxicity of the compounds was determined simultaneously on the same plate in uninfected CEM-SS cells.
- MAGI assay galactosidase indicator assay
- the cells were cultured at 37°C in 5% C0 2 -containing humidified air in the absence or presence of test compounds for 48hrs, followed by fixation with 1 % formaldehyde and 0.2 % glutaraldehyde in PBS for 5 min. The cells were then washed with PBS and incubated in staining solution, containing 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM MgCl 2 , and 0.4 mg/ml X-Gal. HIN-infected indicator cells, which appeared as blue cells, were counted under a light microscope.
- SPR Surface Plasmon Resonance
- the buffer for all SPR experiments was lOmM Hepes pH 7.5, 150mM ⁇ aCl, 5% DMSO, 0.04% polyethylene glycol (PEG) 20000, l ⁇ M ZnCl 2 , 0.005% Tween20, lOO ⁇ M Tris[2-carboxyethyl]phosphine (TCEP), 5mM ⁇ -mercaptoethanol.
- Solution affinity experiments were performed as follows; 50nM NC-p7 was incubated with decreasing amounts of compound and incubated at room temperature for 30mins.
- the second stage of the analysis consisted of docking the test ligands at the candidate binding sites. Docking the candidate ligands was based on geometric considerations using a 'geometric hashing technique' which has been found to rapidly determine a family of possible binding geometries for each ligand. Each of the possible binding arrangements was further refined to determine those positions with the maximum binding strength between ligand and target. A previously published model of ligand binding (Wallqvist & Covell, Proteins 25:403-419, 1996) was used to select the best binding geometries.
- This model is based on the atomic preferences of adjacent surfaces buried within a binding interface and has been shown to accurately predict ligand binding strengths and assess the relative contributions of atomic interactions within a binding interface (Covell & Jernigan, J. Molec. Struct 423:93-100, 1998).
- the model has been extended as an adjunct to computational docking and has been useful for identifying ligands effective against NCp7 targets (Turpin et al, J. Med. Chem 42:67-86, 1999) and providing testable hypotheses about the modes of action of candidate compounds to inhibit each molecule's function (Huang et al, J. Med. Chem 41:1371-1381,1998).
- the final stage of docking was obtained from successive in vacuo molecular dynamics and energy minimizations using the CNFF91 force field within Disco ver97.0(MSI) based on the candidate geometries obtained from steps one and two as outlined above.
- This final step resulted in changes in ligand and target geometries, primarily to eliminate energetically unfavorable van der Waals clashes.
- These dynamics and minimization steps were done repeatedly to achieve the final geometries. Local exploration of the final geometries that were used for the analysis indicated trapping in a local energy minimum.
- Chemical purification procedure Chemicals were purified using a Waters Millennium 32 HPLC system equipped with a Waters 996 photodiode array detector and a Waters ZMD mass spectrometer. Purification of the starting material was performed on a Waters 5 ⁇ M Xterra C18 HPLC column (300mm X 19mm) using a mobile phase gradient of acetonitrile/methanol-20mM aqueous ammonium acetate pH 4.0 with glacial acetic acid. The eluent from 7 chromatographic runs was pooled based on the presence of a strong 503 AMU peak in positive ion mode. The samples were dried by rotary evaporation to remove the organic solvent followed by lyophillization to remove water.
- Synthesis of fluorescein and gallein derivatives Synthesis of the fluorescein and gallein derivatives was done by condensation of the appropriate phthalic anhydride with an excess of resorcinol or pyrogallol by the "hot melt method" (U.S. Patent No. 5,637,733.). Resorcinol (or pyrogallol) was placed in a round bottom flask and heated to 135 oC (or 140°C) to completely melt the crystals. The halogenated phthalic anhydride was added and temperature raised to 200°C for 2 hrs. After cooling to 40°C the crude reaction mixture was precipitated in ice-cold water.
- the fine suspension was centrifuged giving a brightly colored pellet, which was washed several times by re-suspending in ice-cold water and centrifuging. After the final washing the pellet was freeze-dried to form a finely dispersed powder.
- the targeted compound was purified as the fully acetylated derivative (Wei et al, J. Org. Chem. 62:6469-6475, 1997).
- the crude reaction product was dissolved in anhydrous pyridine with a 10 to 20 fold excess of acetic anhydride and magnetically stirred, in an oil bath at 40°C for 8 hours. Excess pyridine and acetic anhydride was removed by partitioning between dichloromethane-aqueous HC1, pH4.0.
- the acetate groups were removed by re-dissolving the crystals in tetrahydrofuran-methanol (1:1) with an excess of ammonium hydroxide ( ⁇ 5 or ⁇ 10 equivalents), stirring at room temperature for 8 hours. After this time, if any acetylated product was detectable by C-18 HPLC analysis, a second addition of ammonium hydroxide was added and the reaction was left overnight at room temperature. An equal volume of water was added to the reaction flask and 5% aqueous hydrochloric acid was used to lower the pH to 5. The organic solvents were removed by rotary evaporation, then freeze-dried to yield a finely dispersed color powder.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002256991A AU2002256991A1 (en) | 2001-02-05 | 2002-02-05 | Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26666501P | 2001-02-05 | 2001-02-05 | |
US60/266,665 | 2001-02-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002062333A1 WO2002062333A1 (en) | 2002-08-15 |
WO2002062333A8 WO2002062333A8 (en) | 2002-10-03 |
WO2002062333A9 true WO2002062333A9 (en) | 2003-01-30 |
Family
ID=23015497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003592 WO2002062333A1 (en) | 2001-02-05 | 2002-02-05 | Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002256991A1 (en) |
WO (1) | WO2002062333A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7572828B2 (en) | 2002-10-08 | 2009-08-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid |
EP1947943A4 (en) * | 2005-10-21 | 2009-11-25 | Univ Alabama | Small molecule inhibitors of hiv-1 capsid assembly |
US9273022B2 (en) | 2009-09-18 | 2016-03-01 | Provectus Pharmaceuticals, Inc. | Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes |
JP5671040B2 (en) * | 2009-09-18 | 2015-02-18 | プロヴェクタス ファーマスーティカルズ,インク. | 4,5,6,7-tetrachloro-3 ', 6'-dihydroxy-2', 4 ', 5', 7'-tetraiodo-3H-spiro [isobenzofuran-1,9'-xanthene] -3- Process for synthesizing on (rose bengal) and related xanthenes |
KR20230005181A (en) * | 2020-03-26 | 2023-01-09 | 프로벡투스 파마테크 인코포레이티드 | Novel Uses of Halogenated Xanthenes in Oncology and Virology |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2678997A (en) * | 1996-04-19 | 1997-11-12 | Lexigen Pharmaceuticals Corp. | Inhibition of the binding of human ige to its receptor by tetracyclic compounds for the alleviation of ige-mediated immune response |
US6140338A (en) * | 1996-07-29 | 2000-10-31 | Banyu Pharmaceutical, Co., Ltd. | Chemokine receptor antagonists |
-
2002
- 2002-02-05 AU AU2002256991A patent/AU2002256991A1/en not_active Abandoned
- 2002-02-05 WO PCT/US2002/003592 patent/WO2002062333A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2002256991A1 (en) | 2002-08-19 |
WO2002062333A8 (en) | 2002-10-03 |
WO2002062333A1 (en) | 2002-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9889115B2 (en) | Fitness assay and associated methods | |
US8076372B2 (en) | Acythiols and component thiol compositions as anti-HIV and anti-retroviral agents | |
KR20080059634A (en) | Composition and synthesis of new reagents for inhibition of hiv replication | |
WO2009061856A1 (en) | Non-nucleoside reverse transcriptase inhibitors | |
CA2260128A1 (en) | Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof | |
KR20170032324A (en) | Phenyl and tertbutylacetic acid substituted pyridinones having anti-hiv effects | |
AU2002322721A1 (en) | Acylthiols and component thiol compositions as anti-HIV and anti-retroviral agents | |
Curreli et al. | Design, synthesis, and antiviral activity of a series of CD4-mimetic small-molecule HIV-1 entry inhibitors | |
US20130096092A1 (en) | Thioether prodrug compositions as anti-hiv and anti-retroviral agents | |
WO2002062333A9 (en) | Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein | |
US7625917B2 (en) | Thiolesters and uses thereof | |
US7572828B2 (en) | Identification of anti-HIV compounds inhibiting virus assembly and binding of nucleocapsid protein to nucleic acid | |
EP1087941B9 (en) | Thiolesters and uses thereof | |
CN102834381A (en) | Derivatives of pyridoxine for inhibiting HIV integrase | |
EP4052726A1 (en) | Cd4 mimic compound with anti-hiv activity | |
AU2004200629B2 (en) | Method of treating HIV infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |